VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

Hope S. Rugo, MD
Published: Monday, Aug 28, 2017



Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Longer-term follow-up is important to determine the benefit of adjuvant hormone therapy, explains Rugo. There is a study with a 7-year follow-up for patients receiving hormone therapy, but it is still unknown whether one can expect to see any different results after long-term treatment.

Additionally, genomic predictors will be beneficial to determine which patients should be treated with this therapy and this is currently being investigated, states Rugo.
 


Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Longer-term follow-up is important to determine the benefit of adjuvant hormone therapy, explains Rugo. There is a study with a 7-year follow-up for patients receiving hormone therapy, but it is still unknown whether one can expect to see any different results after long-term treatment.

Additionally, genomic predictors will be beneficial to determine which patients should be treated with this therapy and this is currently being investigated, states Rugo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x